ArticleImmunotherapy2023

Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.

Millie Das et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.